NG
ONXX

NatWest Group’s ONYX PHARMACEUTICALS INC ONXX Stock Holding History

NatWest Group’s Portfolio ONXX Stock Details ONXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-3,443
Closed -$299K – 1077
2013
Q2 		$299K Buy
+3,443
New +$317K ﹤0.01% 672

Other funds holding ONXX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NatWest Group's ONXX Position: Q3 2013 in Review

NatWest Group sold out of ONYX PHARMACEUTICALS INC (ONXX) in Q3 2013, closing a stake of 3,443 shares — an estimated $299K sold.

NatWest Group first reported a position in ONXX in Q2 2013 and held it in 1 quarter. The position peaked at $299K in Q2 2013. 258 funds tracked by Wall St. Rank hold ONXX as of Q3 2013.

  • NatWest Group reported no remaining ONYX PHARMACEUTICALS INC position as of Q3 2013 after selling out during the quarter.
  • NatWest Group sold 3,443 ONYX PHARMACEUTICALS INC shares in Q3 2013, an estimated $299K.
  • NatWest Group first reported a position in ONYX PHARMACEUTICALS INC in Q2 2013 and held it in 1 quarter.
  • NatWest Group's ONYX PHARMACEUTICALS INC position peaked at $299K in Q2 2013.
  • 258 funds tracked by Wall St. Rank held ONYX PHARMACEUTICALS INC as of Q3 2013.

Based on NatWest Group's 13F filing for Q3 2013, filed 14 Nov 2013.